Volastra Therapeutics Revenue

Biotechnology Research • Manhattan, New York, United States • 21-50 Employees

Volastra Therapeutics revenue & valuation

Annual revenue	$11,500,000
Revenue per employee	$262,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$36,800,000
Total funding	$105,100,000

Key Contacts at Volastra Therapeutics

Charles Hugh-Jones

Ceo

David Southwell

Chief Executive Officer

Kassoum Nacro

Director Of Chemistry

Rafael Depetris

Director, Biochemistry And Structural Biology

Maeve Morse-Seaverns

Associate Director, Business & Portfolio Strategy

Swathi Pinnamaneni

Associate Director

Celia Andreu-Agullo

Senior Director

Cindy O.

Senior Director, Clinical & Business Operations

Company overview

Headquarters	1361 Amsterdam Ave, 520, New York, New York 10027, US
Phone number	+16463441248
Website	volastratx.com
SIC	873
Founded	2019
Employees	21-50
Socials

Volastra Therapeutics Email Formats

Volastra Therapeutics uses 2 email formats. The most common is {first name}{last name} (e.g., johndoe@volastratx.com), used 51.6% of the time.

Format	Example	Percentage
{first name}{last name}	johndoe@volastratx.com	51.6%
{first initial}{last name}	jdoe@volastratx.com	48.4%

About Volastra Therapeutics

Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancer’s most targetable vulnerability. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is advancing a novel synthetic lethal and immune activating pipeline. Leading its portfolio, Volastra has two KIF18A inhibitors in Phase 1 clinical trials for cancers with high levels of chromosomal instability.

Employees by Management Level

Total employees: 21-50

Seniority

Employees

Entry

Director

Senior

Employees by Department

Volastra Therapeutics has 20 employees across 10 departments.

Departments

Number of employees

Funding Data

Explore Volastra Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount
2023-04-07	4	$60,000,000
2024-06-30	1	$15,000,000
2025-10-23	1	$30,100,000

Funding Insights

$105,100,000

Total funding amount

$30,100,000

Most recent funding amount

Number of funding rounds

Volastra Therapeutics Tech Stack

Discover the technologies and tools that power Volastra Therapeutics's digital infrastructure, from frameworks to analytics platforms.

Site Kit

Analytics

PWA

Miscellaneous

Swiper

JavaScript libraries

lit-element

JavaScript libraries

jQuery UI

JavaScript libraries

Google Maps

Maps

Elementor

Page builders

lit-html

JavaScript libraries

Zendesk

Documentation

Twitter Emoji

Font scripts

jQuery

JavaScript libraries

Tippy.js

JavaScript libraries

Frequently asked questions

Volastra Therapeutics is located in Manhattan, New York, US.

You can reach Volastra Therapeutics at +16463441248.

Volastra Therapeutics generates an estimated annual revenue of $11,500,000. This revenue figure reflects the company's market position and business performance in its industry.

Volastra Therapeutics has an estimated valuation of $36,800,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Volastra Therapeutics was founded in 2019, making it 7 years old. The company has established itself as a significant player in its industry over this time.

Volastra Therapeutics has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.

Volastra Therapeutics has raised a total of $105,100,000 across 3 funding rounds. This investment has helped the company grow and expand its operations.

Key Contacts at Volastra Therapeutics

Charles Hugh-Jones

Ceo

David Southwell

Chief Executive Officer

Kassoum Nacro

Director Of Chemistry

Rafael Depetris

Director, Biochemistry And Structural Biology

Maeve Morse-Seaverns

Associate Director, Business & Portfolio Strategy

Swathi Pinnamaneni